By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

RegeneRx Biopharmaceuticals, Inc. 

3 Bethesda Metro Center, Suite 630

Bethesda  Maryland  20814  U.S.A.
Phone: 301-280-1992 Fax: 301-280-1996


SEARCH JOBS








Company News
RegeneRx Biopharmaceuticals, Inc. (RGRX) To Present At Rodman & Renshaw 18th Annual Global Investment Conference 8/30/2016 11:55:17 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Intent To Grant Patent For The Treatment Of Patients With Multiple Sclerosis In EUrege 8/29/2016 8:45:28 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Joint Venture To Begin Second Phase 3 Study Of RGN-259 For Dry Eye Syndrome In 3rd Quarter 8/24/2016 7:07:21 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Allowance For Key U.S. Patent That Expands And Extends Exclusivity Of Company's Product Candidates 8/3/2016 12:20:48 PM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Announces $1.75 Million Private Placement 6/27/2016 8:46:01 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Thymosin Beta 4 Effective In Treatment Of Heart Attack Patients 6/15/2016 11:48:09 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) And Lee's Pharmaceutical Announce Acceleration Of RGN-259 Development In China 6/1/2016 4:18:30 PM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Comments On Valuation 5/31/2016 8:11:15 AM
Rodman & Renshaw Updates Analyst Report On RegeneRx Biopharmaceuticals, Inc. (RGRX) With Buy Rating 5/10/2016 11:52:41 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: RGN-259 Confirms Efficacy In Signs And Symptoms Of Dry Eye 5/6/2016 6:44:02 AM
12345678910...
//-->